+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06897644

Comparing Gemcitabine Plus Nab-Paclitaxel Switch Maintenance to Continuing Modified FOLFIRINOX in Advanced Pancreatic Cancer PANThEON Phase III Trial

Led by Gruppo Oncologico del Nord-Ovest · Updated on 2026-09-09

340

Participants Needed

28

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting the PANThEON trial, a randomized, open-label, multicenter phase III study, to compare two chemotherapy approaches in patients with advanced pancreatic adenocarcinoma that cannot be surgically removed or has spread. The study aims to evaluate overall survival by comparing continuing modified FOLFIRINOX versus switching to gemcitabine plus nab-paclitaxel after initial induction chemotherapy. Eligible patients have stable or responding disease after about 3 months of initial mFOLFIRINOX treatment. During the study, all participants first receive induction chemotherapy with mFOLFIRINOX for up to 14 weeks, consisting of about six cycles every two weeks. Patients who show no disease progression are then randomly assigned to either continue mFOLFIRINOX Arm A or switch to gemcitabine plus nab-paclitaxel Arm B. Arm A treatments include oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil given every two weeks until progression or unacceptable side effects. Arm B treatments involve gemcitabine and nab-paclitaxel administered on days 1, 8, and 15 of each 28-day cycle until progression or toxicity. Participants will have tumor imaging before and after induction chemotherapy to assess response. Throughout the trial, researchers will monitor overall survival up to 48 months, along with other outcomes like progression-free survival, treatment failure time, response rates, quality of life, and treatment toxicity. Safety and disease status will be regularly assessed, and participants may continue treatment or withdraw as needed. The trial is expected to last until 2030, with ongoing follow-up for health status and outcomes.

CONDITIONS

Brief Title

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Research Team

M

Monica Niger, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here